Jay Edelberg
Director/Board Member chez Prolaio, Inc.
Profil
Actuellement, Jay Edelberg occupe le poste de premier vice-président du développement clinique chez MyoKardia, Inc. Dans sa carrière précédente, il a occupé le poste de chef de l'unité de développement et de lancement chez Sanofi. Le Dr Edelberg a obtenu un doctorat de l'université de Duke.
Postes actifs de Jay Edelberg
| Sociétés | Poste | Début |
|---|---|---|
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Director/Board Member | - |
Anciens postes connus de Jay Edelberg
| Sociétés | Poste | Fin |
|---|---|---|
| MYOKARDIA, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
| SANOFI | Corporate Officer/Principal | - |
Formation de Jay Edelberg
| Duke University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SANOFI | Health Technology |
| Entreprise privées | 2 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
